KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals (NASDAQ: KALV) has announced the granting of inducement stock options to 52 newly-hired employees. The compensation committee approved options to purchase a total of 261,000 shares of KalVista common stock on February 3, 2025. The exercise price matches the closing price of KalVista stock on the grant date.
The vesting schedule includes 25% of options vesting after one year, with the remaining options vesting in equal monthly installments over the following three years, contingent on continued employment. The options have a 10-year term and are governed by KalVista's Inducement Equity Incentive Plan and individual stock option agreements, in compliance with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) ha annunciato la concessione di opzioni su azioni come incentivo a 52 nuovi dipendenti. Il comitato per le compensazioni ha approvato opzioni per l'acquisto di un totale di 261.000 azioni di azioni ordinarie di KalVista il 3 febbraio 2025. Il prezzo di esercizio corrisponde al prezzo di chiusura delle azioni KalVista nella data di concessione.
Il programma di vesting prevede che il 25% delle opzioni maturi dopo un anno, con le restanti opzioni che maturano in rate mensili uguali nei tre anni successivi, a condizione di continuare a lavorare. Le opzioni hanno una durata di 10 anni e sono regolate dal Piano di Incentivi in Equity di KalVista e da singoli accordi di opzione su azioni, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) ha anunciado la concesión de opciones sobre acciones como incentivo a 52 nuevos empleados. El comité de compensación aprobó opciones para comprar un total de 261,000 acciones de acciones ordinarias de KalVista el 3 de febrero de 2025. El precio de ejercicio coincide con el precio de cierre de las acciones de KalVista en la fecha de concesión.
El programa de adquisición incluye que el 25% de las opciones se adquirirá después de un año, con las opciones restantes adquiriéndose en cuotas mensuales iguales durante los siguientes tres años, condicionado a la continuidad del empleo. Las opciones tienen un plazo de 10 años y están regidas por el Plan de Incentivos de Capital de KalVista y acuerdos individuales de opción sobre acciones, en cumplimiento con la Regla de Cotización 5635(c)(4) de Nasdaq.
KalVista Pharmaceuticals (NASDAQ: KALV)는 52명의 신규 직원에게 유인 주식 옵션을 부여한다고 발표했습니다. 보상 위원회는 2025년 2월 3일에 KalVista 보통주 261,000주를 구매할 수 있는 옵션을 승인했습니다. 행사 가격은 부여일의 KalVista 주식 종가와 일치합니다.
권리 확보 일정은 1년 후 25%의 옵션이 발생하며, 나머지 옵션은 향후 3년 동안 균등한 월별 할부로 발생하며, 지속적인 근무를 조건으로 합니다. 이 옵션은 10년의 기간을 가지며, KalVista의 유인 주식 인센티브 계획 및 개별 주식 옵션 계약에 따라 Nasdaq 상장 규칙 5635(c)(4) 준수합니다.
KalVista Pharmaceuticals (NASDAQ: KALV) a annoncé l'octroi d'options d'achat d'actions incitatives à 52 nouveaux employés. Le comité de rémunération a approuvé des options pour acheter un total de 261.000 actions de KalVista au 3 février 2025. Le prix d'exercice correspond au prix de clôture de l'action KalVista à la date d'octroi.
Le calendrier d'acquisition prévoit que 25 % des options acquièrent leur valeur après un an, les options restantes acquérant leur valeur par versements mensuels égaux au cours des trois années suivantes, sous réserve d'une continuation de l'emploi. Les options ont une durée de 10 ans et sont régies par le Plan d'Incentives en Équité de KalVista et des accords individuels d'options d'achat d'actions, en conformité avec la Règle de Cotation 5635(c)(4) de Nasdaq.
KalVista Pharmaceuticals (NASDAQ: KALV) hat die Gewährung von Anreiz-Stockoptionen an 52 neu eingestellte Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte Optionen zum Kauf von insgesamt 261.000 Aktien von KalVista-Hauptaktien am 3. Februar 2025. Der Ausübungspreis entspricht dem Schlusskurs der KalVista-Aktien am Tag der Gewährung.
Der Vesting-Zeitplan sieht vor, dass 25% der Optionen nach einem Jahr fällig werden, während die verbleibenden Optionen in gleichen monatlichen Raten über die folgenden drei Jahre fällig werden, vorausgesetzt, dass das Arbeitsverhältnis fortgesetzt wird. Die Optionen haben eine Laufzeit von 10 Jahren und unterliegen dem Anreiz-Equity-Plan von KalVista sowie den individuellen Optionenverträgen, gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- Significant workforce expansion with 52 new hires indicates company growth
- Stock-based compensation aligns employee interests with shareholder value
- Potential shareholder dilution from 261,000 new stock options
One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.
The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the
For more information about KalVista, please visit www.kalvista.com or follow on social media at @KalVista and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204778137/en/
KalVista Pharmaceuticals, Inc.
Media:
Jenn Snyder
Vice President, Corporate Affairs
(857) 356-0479
jennifer.snyder@kalvista.com
Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Source: KalVista Pharmaceuticals, Inc.
FAQ
How many shares were granted in KALV's February 2025 inducement options?
What is the vesting schedule for KALV's February 2025 inducement options?
How many new employees received KALV stock options in February 2025?
What is the term length of KALV's February 2025 inducement options?
What is the exercise price for KALV's February 2025 inducement options?
